Overseas-registered products available for cyclophosphamide and ifosfamide injection shortages
AustraliaOverseas-registered products available for cyclophosphamide and ifosfamide injection shortages
Recalling Firm: TGA
Reason for Recall / Hazard
Information about the cyclophosphamide and ifosfamide injection shortages....
Product Description & Identification
Information about the cyclophosphamide and ifosfamide injection shortages.
Affected Products
Overseas-registered products available for cyclophosphamide and ifosfamide injection shortages
Additional Source Details
| Field | Value |
|---|---|
| Guid › #text | https://www.tga.gov.au/node/558843 |
| Guid › @ is Perma Link | true |
| Link | https://www.tga.gov.au/safety/shortages-and-supply-disruptions/medicine-shortages/medicine-shortage-alerts/overseas-registered-products-available-cyclophosphamide-and-ifosfamide-injection-shortages |
| Pub Date | Wed, 22 Apr 2026 00:00:00 +1000 |
| Extracted category | drugs |
Overview
- Recalling FirmTGA
- Risk LevelMedicines Safety Alert
- DistributionAustralia
📢 Share Warning
Alert family and friends to keep them safe. Copy this quick alert message:
🚨 SAFETY ALERT: TGA - Overseas-registered products available for cyclophosphamide and ifosfamide injection shortages Check if your household is affected: https://therecallfile.com/recalls/overseas-registered-products-available-for-cyclophosphamide-and-ifosfa/AU-TGA-558843
Join Alertlist
Get instant email updates whenever critical safety recalls like this are published.
Related Recalls
UKClass 4 Medicines Defect Notification: Neuraxpharm UK Ltd, Tuzulby prolonged-release chewable tablets, EL(26)A/36
Class 4 Medicines Defect Notification: Neuraxpharm UK Ltd, Tuzulby prolonged-release chewable tablets, EL(26)A/36
Neuraxpharm UK Ltd has informed the MHRA of missing safety information in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for certain batches of Tuzulby prolonged r...
AustraliaGLP-1 RAs and rare, but severe, eye disorders
GLP-1 RAs and rare, but severe, eye disorders
Product warnings across the GLP-1 RA class of medicines have been updated due to the potential for these products to cause a rare, but severe, form of eye disorder....
UKClass 4 Medicines Defect Notification: Macarthys Laboratories Ltd T/A Martindale Pharma, Xaggitin XL Prolonged-release Tablets, EL(26)A/35
Class 4 Medicines Defect Notification: Macarthys Laboratories Ltd T/A Martindale Pharma, Xaggitin XL Prolonged-release Tablets, EL(26)A/35
Macarthys Laboratories Ltd T/A Martindale Pharma has notified the MHRA of a manufacturing issue impacting several batches of Xaggitin XL Prolonged-release Tablets, due to the occurrence of incorrect t...